• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可溶性环氧化物水解酶抑制剂在代谢及相关心血管疾病中的临床观察

A Clinical Perspective of Soluble Epoxide Hydrolase Inhibitors in Metabolic and Related Cardiovascular Diseases.

机构信息

Department of Pharmacy, Banasthali Vidyapith Banasthali, P.O. Rajasthan 304022, India.

Department of Bioscience and Biotechnology, Banasthali Vidyapith, Banasthali 304022, Rajasthan, India.

出版信息

Curr Mol Pharmacol. 2022;15(5):763-778. doi: 10.2174/1874467214666210920104352.

DOI:10.2174/1874467214666210920104352
PMID:34544352
Abstract

Epoxide hydrolase (EH) is a crucial enzyme responsible for catabolism, detoxification, and regulation of signaling molecules in various organisms including human beings. In mammals, EHs are classified according to their DNA sequence, sub-cellular location, and activity into eight major classes: soluble EH (sEH), microsomal EH (mEH), leukotriene A4 hydrolase (LTA4H), cholesterol EH (ChEH), hepoxilin EH, paternally expressed gene 1 (peg1/MEST), EH3, and EH4. The sEH, an α/β-hydrolase fold family enzyme, is an emerging pharmacological target in multiple diseases namely, cardiovascular disease, neurodegenerative disease, chronic pain, fibrosis, diabetes, pulmonary diseases, and immunological disease. It exhibits prominent physiological effects including anti-inflammatory, anti-migratory, and vasodilatory effects. Its efficacy has been documented in various clinical trials and observational studies. This review specifically highlights the development of soluble epoxide hydrolase inhibitors (sEHIs) in the clinical setting for the management of metabolic syndrome and related disorders, such as cardiovascular effects, endothelial dysfunction, arterial disease, hypertension, diabetes, obesity, heart failure, and dyslipidemia. In addition, limitations and future aspects of sEHIs have also been highlighted which will help the investigators to bring the sEHI to the clinics.

摘要

环氧化物水解酶(EH)是一种在包括人类在内的各种生物体中负责分解代谢、解毒和调节信号分子的关键酶。在哺乳动物中,EH 根据其 DNA 序列、亚细胞位置和活性分为八大类:可溶性 EH(sEH)、微粒体 EH(mEH)、白三烯 A4 水解酶(LTA4H)、胆固醇 EH(ChEH)、海鞘素 EH、父系表达基因 1(peg1/MEST)、EH3 和 EH4。sEH 是一种 α/β-水解酶折叠家族酶,是多种疾病(如心血管疾病、神经退行性疾病、慢性疼痛、纤维化、糖尿病、肺部疾病和自身免疫性疾病)的新兴药理学靶点。它具有显著的生理作用,包括抗炎、抗迁移和血管舒张作用。其疗效已在各种临床试验和观察性研究中得到证实。本综述特别强调了可溶性环氧化物水解酶抑制剂(sEHIs)在代谢综合征及其相关疾病(如心血管效应、内皮功能障碍、动脉疾病、高血压、糖尿病、肥胖、心力衰竭和血脂异常)管理中的临床应用进展。此外,还强调了 sEHIs 的局限性和未来发展方向,这将有助于研究人员将 sEHI 推向临床。

相似文献

1
A Clinical Perspective of Soluble Epoxide Hydrolase Inhibitors in Metabolic and Related Cardiovascular Diseases.可溶性环氧化物水解酶抑制剂在代谢及相关心血管疾病中的临床观察
Curr Mol Pharmacol. 2022;15(5):763-778. doi: 10.2174/1874467214666210920104352.
2
Soluble epoxide hydrolase inhibitors and cardiovascular diseases.可溶性环氧化物水解酶抑制剂与心血管疾病。
Curr Vasc Pharmacol. 2013 Jan;11(1):105-11.
3
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.可溶性环氧化物水解酶作为心血管疾病的治疗靶点。
Nat Rev Drug Discov. 2009 Oct;8(10):794-805. doi: 10.1038/nrd2875.
4
Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade.可溶性环氧化物水解酶抑制剂:过去十年的概述及专利研究
Expert Opin Ther Pat. 2022 Jun;32(6):629-647. doi: 10.1080/13543776.2022.2054329. Epub 2022 Apr 12.
5
Epoxide hydrolases: their roles and interactions with lipid metabolism.环氧水解酶:它们在脂质代谢中的作用及相互作用
Prog Lipid Res. 2005 Jan;44(1):1-51. doi: 10.1016/j.plipres.2004.10.001. Epub 2005 Jan 25.
6
Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism.可溶性和微粒体环氧化物水解酶在小鼠脑中的分布及其对脑内环氧二十碳三烯酸代谢的作用。
Neuroscience. 2009 Oct 6;163(2):646-61. doi: 10.1016/j.neuroscience.2009.06.033. Epub 2009 Jun 18.
7
The soluble epoxide hydrolase as a pharmaceutical target for hypertension.可溶性环氧化物水解酶作为高血压的药物靶点。
J Cardiovasc Pharmacol. 2007 Sep;50(3):225-37. doi: 10.1097/FJC.0b013e3181506445.
8
Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.可溶性环氧化物水解酶:心血管疾病的一个有前景的治疗靶点。
Pharmazie. 2011 Mar;66(3):153-7.
9
Beyond detoxification: a role for mouse mEH in the hepatic metabolism of endogenous lipids.超越解毒:小鼠 mEH 在肝脏代谢内源性脂质中的作用。
Arch Toxicol. 2017 Nov;91(11):3571-3585. doi: 10.1007/s00204-017-2060-4. Epub 2017 Oct 3.
10
Relative Importance of Soluble and Microsomal Epoxide Hydrolases for the Hydrolysis of Epoxy-Fatty Acids in Human Tissues.可溶性和微粒体环氧化物水解酶对人组织中环氧脂肪酸水解的相对重要性。
Int J Mol Sci. 2021 May 8;22(9):4993. doi: 10.3390/ijms22094993.

引用本文的文献

1
Exploring hypertension-linked diseases: a comprehensive review of innovative drug combinations with enhanced therapeutic potential.探索与高血压相关的疾病:对具有增强治疗潜力的创新药物组合的全面综述。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan 31. doi: 10.1007/s00210-025-03819-3.
2
Salt-sensitive hypertension in GR mutant rats is associated with altered plasma polyunsaturated fatty acid levels and aortic vascular reactivity.GR突变大鼠的盐敏感性高血压与血浆多不饱和脂肪酸水平改变及主动脉血管反应性有关。
Pflugers Arch. 2025 Jan;477(1):37-53. doi: 10.1007/s00424-024-03014-y. Epub 2024 Sep 10.
3
Preclinical Evaluation of Soluble Epoxide Hydrolase Inhibitor AMHDU against Neuropathic Pain.
可溶性环氧化物水解酶抑制剂 AMHDU 抗神经病理性疼痛的临床前评价。
Int J Mol Sci. 2024 Aug 14;25(16):8841. doi: 10.3390/ijms25168841.
4
Ureas derived from camphor and fenchone reveal enantiomeric preference of human soluble epoxide hydrolase.源自樟脑和葑酮的脲类化合物揭示了人可溶性环氧化物水解酶的对映体偏好性。
Results Chem. 2022 Jan;4. doi: 10.1016/j.rechem.2022.100653. Epub 2022 Nov 16.
5
Sex-Specific Response of the Brain Free Oxylipin Profile to Soluble Epoxide Hydrolase Inhibition.脑游离氧代脂反应的性别特异性对可溶性环氧化物水解酶抑制作用。
Nutrients. 2023 Feb 28;15(5):1214. doi: 10.3390/nu15051214.
6
Soluble Epoxide Hydrolase Inhibitor t-AUCB Ameliorates Vascular Endothelial Dysfunction by Influencing the NF-κB/miR-155-5p/eNOS/NO/IκB Cycle in Hypertensive Rats.可溶性环氧化物水解酶抑制剂t-AUCB通过影响高血压大鼠的NF-κB/miR-155-5p/eNOS/NO/IκB循环改善血管内皮功能障碍。
Antioxidants (Basel). 2022 Jul 15;11(7):1372. doi: 10.3390/antiox11071372.